All Updates

All Updates

icon
Filter
Funding
Transcend Therapeutics raises USD 40 million in Series A funding
Psychedelic Medicine
Feb 23, 2023
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Feb 23, 2023

Transcend Therapeutics raises USD 40 million in Series A funding

Funding

  • Transcend Therapeutics, a mental health-focused biotechnology company, raised USD 40 million in a Series A funding round led by Alpha Wave Global and Integrated Investment Partners. This brings the total funding raised by the company to USD 42 million. 

  • The funds will be used to launch multiple clinical trials, including a Phase II study, using the firm’s proprietary psychoactive compound, which is claimed to be more accessible than outright psychedelic treatment. 

  • US-based Transcend Therapeutics develops psychoactive drugs aiming to support patients with neuropsychiatric diseases. The company’s lead compound methylone (TSND-201) has demonstrated strong results in patients that suffer from PTSD.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.